| Name | Title | Contact Details |
|---|
Mokveld Valves BV is a Dutch manufacturer with a history dating back to 1922. Originally a machine repair shop, it evolved into a leader in high-pressure axial flow valve technology. The company specializes in valves designed for rapid and reliable isolation in severe-service applications, such as High-Integrity Pressure Protection Systems (HIPPS) and Emergency Shut Down (ESD) systems. Mokvelds product range includes axial flow valves, axial control valves, angle choke valves, and axial choke valves, all engineered for demanding environments. Their valves are known for features like bubble-tight bi-directional sealing and the ability to operate under full differential pressure. Mokveld serves a global customer base in the energy sector, including oil and gas production, transmission, and processing, as well as the water industry. The company is recognized for its commitment to reliability, safety, and environmental performance.
CAC Group operates in two distinct sectors. The first entity, CAC Group (Insurance & Advisory Services), is a prominent insurance broker and advisor. They specialize in customized solutions for insurance and capital markets, offering advisory and placement services for complex risk management. They also provide bespoke financial solutions through CAC Capital, focusing on private finance and structured offerings. In August 2024, they launched a new brand identity to reflect their expanded capabilities. The second entity, CAC Holdings Corporation, is a Japanese IT services conglomerate established in 1966. With 23 subsidiaries worldwide, it provides IT system construction, operation, and strategic consulting for enterprises. The company is led by President and CEO Ryota Nishimori and has a consolidated workforce of 4,653 employees. As of December 2024, CAC Holdings reported a capital of ¥3.7 billion and consolidated sales of ¥52.06 billion.
As a leading franchise brokerage firm in the USA and Canada, Klimate Group is renowned for its exceptional reputation in the industry. Specializing in connecting aspiring entrepreneurs with top franchise opportunities, Klimate Group stands out for its extensive network of franchisors, personalized guidance for franchisees, and commitment to fostering successful partnerships. With a track record of matching individuals with franchises that align with their goals and values, Klimate Group has established itself as a trusted and innovative player in the franchising world, setting the standard for excellence and professionalism.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.